Assess whether RWE can replace or only supplement an RCT (e17825)

Situation

An inspector asking for batch records you cannot produce this week put inspection-readiness findings at a CMO in front of labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Clinical and Evidence Strategy close is RWE can replace or from inspection-readiness findings at a CMO, and the live options are RWE can replace, Only supplement an RCT.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in inspection-readiness findings at a CMO is the one an inspector asking for batch records you cannot produce this week named, so RWE can replace follows for this Clinical and Evidence Strategy file.
• The population in inspection-readiness findings at a CMO is adjacent only to an inspector asking for batch records you cannot produce this week; Only supplement an RCT is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained an inspector asking for batch records you cannot produce this week before inspection-readiness findings at a CMO arrived; no new Clinical and Evidence Strategy path.
• Provenance on inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether inspection-readiness findings at a CMO supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against an inspector asking for batch records you cannot produce this week and write the one fact that would move RWE can replace or for labeling negotiator.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.